HZNP Stock - Horizon Pharma Inc.

HZNP Stock Chart

HZNP Profile

orizon Therapeutics Public Limited Company, a prominent biotechnology firm headquartered in Dublin, Ireland, specializes in the discovery, development, and commercialization of therapeutic solutions targeting rare, autoimmune, and severe inflammatory diseases. Established in 2005, the company operates through two core segments: Orphan and Inflammation, offering a robust portfolio of 12 medicines spanning areas such as rare diseases, gout, ophthalmology, and inflammation.

The company's flagship products include TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic gout, and RAVICTI for urea cycle disorders, among others. These treatments cater to critical medical needs, providing innovative solutions that enhance quality of life for patients globally.

Horizon Therapeutics maintains a strategic focus on expanding its pipeline through collaborations with leading biopharmaceutical entities such as HemoShear Therapeutics, Alpine Immune Sciences, and Arrowhead Pharmaceuticals. These partnerships underscore Horizon's commitment to advancing cutting-edge therapies and leveraging synergies to drive scientific innovation.

With offices across major hubs in the United States and Germany, including Deerfield, Chicago, and Mannheim, Horizon Therapeutics operates at the forefront of biotechnological advancement. The company's geographical footprint supports its global outreach and facilitates collaborations with research institutions and healthcare providers, reinforcing its position as a leader in specialized medicine development.

HZNP Revenue Chart

HZNP Earnings

Analyst Ratings